Roles of Medicinal Plants and Constituents in Gynecological Cancer Therapy: Current Literature and Future Directions

Author(s): Esra Küpeli Akkol*, Fatma Tuğçe Gürağaç Dereli, Eduardo Sobarzo-Sánchez, Haroon Khan

Journal Name: Current Topics in Medicinal Chemistry

Volume 20 , Issue 20 , 2020

DOI : 10.2174/1568026620666200416084440

  Journal Home
Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Gynecologic cancers, including cervical, primary peritoneal, ovarian, uterine/endometrial, vaginal and vulvar cancers and gestational trophoblastic disease, are characterized by abnormal cell proliferation in female reproductive cells. Due to the variable pathology of these cancers and the lack of appropriate screening tests in developing countries, cancer diagnosis can be reported in advanced stages in most women and this situation adversely affects prognosis and clinical outcomes of illness. For this reason, many researchers in the field of gynecological oncology have carried out many studies.

The treatment of various gynecological problems, which cause physical, biological and psychosocial conditions such as fear, shame, blame and anger, has been important throughout the history. Treatment with herbs has become popular nowadays due to the serious side effects of the synthetic drugs used in treatment and the medical and economical problems caused by them. Many scientists have identified various active drug substances through in vivo and in vitro biological activity studies on medicinal plants from the past to the present. While the intrinsic complexity of natural product-based drug discoveries requires highly integrated interdisciplinary approaches, scientific and technological advances and research trends clearly show that natural products will be among the most important new drug sources in the future.

In this review, an overview of the studies conducted for the discovery of multitargeted drug molecules in the rational treatment of gynecological cancers is presented.

Keywords: Gynecological oncology, Medicinal plant, Drug molecule, Cancer, Natural product, Female reproductive system.

[1]
W.H.O. (WHO). The World Health Organization’s fight against cancer: Strategies that prevent, cure and care. Available from: https://www.who.int/cancer/publications/fight_against_cancer/en/ (Accessed Nov 12, 2019)
[2]
Boyle, P.; Levin, B. World cancer report international agency for research on cancer; IARC: Geneva, 2008, pp. 1-6.
[3]
Giammarile, F.; Bozkurt, M.F.; Cibula, D.; Pahisa, J.; Oyen, W.J.; Paredes, P.; Olmos, R.V.; Sicart, S.V. The EANM clinical and technical guidelines for lymphoscintigraphy and sentinel node localization in gynaecological cancers. Eur. J. Nucl. Med. Mol. Imaging, 2014, 41(7), 1463-1477.
[http://dx.doi.org/10.1007/s00259-014-2732-8] [PMID: 24609929]
[4]
Mais, V.; Peiretti, M.; Gargiulo, T.; Parodo, G.; Cirronis, M.G.; Melis, G.B. Intraoperative sentinel lymph node detection by vital dye through laparoscopy or laparotomy in early endometrial cancer. J. Surg. Oncol., 2010, 101(5), 408-412.
[http://dx.doi.org/10.1002/jso.21496] [PMID: 20119976]
[5]
Van der Zee, A.G.; Oonk, M.H.; De Hullu, J.A.; Ansink, A.C.; Vergote, I.; Verheijen, R.H.; Maggioni, A.; Gaarenstroom, K.N.; Baldwin, P.J.; Van Dorst, E.B.; Van der Velden, J.; Hermans, R.H.; van der Putten, H.; Drouin, P.; Schneider, A.; Sluiter, W.J. Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. J. Clin. Oncol., 2008, 26(6), 884-889.
[http://dx.doi.org/10.1200/JCO.2007.14.0566] [PMID: 18281661]
[6]
Lu, K.H.; Dinh, M.; Kohlmann, W.; Watson, P.; Green, J.; Syngal, S.; Bandipalliam, P.; Chen, L.M.; Allen, B.; Conrad, P.; Terdiman, J.; Sun, C.; Daniels, M.; Burke, T.; Gershenson, D.M.; Lynch, H.; Lynch, P.; Broaddus, R.R. Gynecologic cancer as a “sentinel cancer” for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet. Gynecol., 2005, 105(3), 569-574.
[http://dx.doi.org/10.1097/01.AOG.0000154885.44002.ae] [PMID: 15738026]
[7]
Ülger, E.; Alacacıoğlu, A.; Gülseren, A.Ş.; Zencir, G.; Demir, L.; Tarhan, M.O. Psychosocial problems in cancer and the importance of psychosocial oncology. Deu Feas. J., 2015, 28, 85-92.
[8]
Weare, K. Rehabilitation after gynecological cancer treatment. Int. J. Gynaecol. Obstet., 2015, 131(2)(Suppl. 2), S164-S166.
[http://dx.doi.org/10.1016/j.ijgo.2015.06.015] [PMID: 26433675]
[9]
Hopman, P.; Rijken, M. Illness perceptions of cancer patients: relationships with illness characteristics and coping. Psychooncology, 2015, 24(1), 11-18.
[http://dx.doi.org/10.1002/pon.3591] [PMID: 24891136]
[10]
Raimond, E.; Ballester, M.; Hudry, D.; Bendifallah, S.; Daraï, E.; Graesslin, O.; Coutant, C. Impact of sentinel lymph node biopsy on the therapeutic management of early-stage endometrial cancer: Results of a retrospective multicenter study. Gynecol. Oncol., 2014, 133(3), 506-511.
[http://dx.doi.org/10.1016/j.ygyno.2014.03.019] [PMID: 24642092]
[11]
Baytop, T. Treatment Plant in Turkey: Past and Present; Nobel: Istanbul, 1999.
[12]
Kara, H.; Aydın, S. Sexual problems and solutions; Sen Publishing: Ankara, 2002.
[13]
Gürkan, E.; Öndersev, D.V.; Ulusoylu, M.; Göztaş, Z.; Dinçşahin, N. Herbal Treatment; Marmara University Publications: Istanbul, 2003.
[14]
Çubukçu, B.; Meriçli, A.H.; Mat, A.; Sarıyar, G.; Sütlüpınar, N.; Meriçli, F. Phytotherapy Supplementary Textbook; Istanbul University Faculty of Pharmacy: Istanbul, 2002.
[15]
Asımgil, A. Şifalı Bitkiler; Timaş Publishing Group: Istanbul, 1997.
[16]
Robinson, D.R.; Wu, Y.M.; Lin, S.F. The protein tyrosine kinase family of the human genome. Oncogene, 2000, 19(49), 5548-5557.
[http://dx.doi.org/10.1038/sj.onc.1203957] [PMID: 11114734]
[17]
Blume-Jensen, P.; Hunter, T. Oncogenic kinase signalling. Nature, 2001, 411(6835), 355-365.
[http://dx.doi.org/10.1038/35077225] [PMID: 11357143]
[18]
Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell, 2000, 103(2), 211-225.
[http://dx.doi.org/10.1016/S0092-8674(00)00114-8] [PMID: 11057895]
[19]
Hubbard, S.R. Juxtamembrane autoinhibition in receptor tyrosine kinases. Nat. Rev. Mol. Cell Biol., 2004, 5(6), 464-471.
[http://dx.doi.org/10.1038/nrm1399] [PMID: 15173825]
[20]
Pawson, T.; Gish, G.D. SH2 and SH3 domains: From structure to function. Cell, 1992, 71(3), 359-362.
[http://dx.doi.org/10.1016/0092-8674(92)90504-6] [PMID: 1423600]
[21]
Brugge, J.S. New intracellular targets for therapeutic drug design. Science, 1993, 260(5110), 918-919.
[http://dx.doi.org/10.1126/science.8388123] [PMID: 8388123]
[22]
Botfield, M.C.; Green, J. SH2 and SH3 domains: Choreographers of multiple signaling pathways. Annu. Rep. Med. Chem., 1995, 30, 227-237.
[http://dx.doi.org/10.1016/S0065-7743(08)60937-9]
[23]
Songyang, Z.; Shoelson, S.E.; Chaudhuri, M.; Gish, G.; Pawson, T.; Haser, W.G.; King, F.; Roberts, T.; Ratnofsky, S.; Lechleider, R.J.; Neel, B.G.; Birge, R.B.; Fajardo, J.E.; Chou, M.M.; Hanafusa, H.; Schaffhausen, B.; Cantley, L.C. SH2 domains recognize specific phosphopeptide sequences. Cell, 1993, 72(5), 767-778.
[http://dx.doi.org/10.1016/0092-8674(93)90404-E] [PMID: 7680959]
[24]
Songyang, Z.; Shoelson, S.E.; McGlade, J.; Olivier, P.; Pawson, T.; Bustelo, X.R.; Barbacid, M.; Sabe, H.; Hanafusa, H.; Yi, T. Specific motifs recognized by the SH2 domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk, and Vav. Mol. Cell. Biol., 1994, 14(4), 2777-2785.
[http://dx.doi.org/10.1128/MCB.14.4.2777] [PMID: 7511210]
[25]
Fruman, D.A.; Meyers, R.E.; Cantley, L.C. Phosphoinositide kinases. Annu. Rev. Biochem., 1998, 67, 481-507.
[http://dx.doi.org/10.1146/annurev.biochem.67.1.481] [PMID: 9759495]
[26]
Vanhaesebroeck, B.; Guillermet-Guibert, J.; Graupera, M.; Bilanges, B. The emerging mechanisms of isoform-specific PI3K signalling. Nat. Rev. Mol. Cell Biol., 2010, 11(5), 329-341.
[http://dx.doi.org/10.1038/nrm2882] [PMID: 20379207]
[27]
Amzel, L.M.; Huang, C.H.; Mandelker, D.; Lengauer, C.; Gabelli, S.B.; Vogelstein, B. Structural comparisons of class I phosphoinositide 3-kinases. Nat. Rev. Cancer, 2008, 8(9), 665-669.
[http://dx.doi.org/10.1038/nrc2443] [PMID: 18633356]
[28]
Geering, B.; Cutillas, P.R.; Nock, G.; Gharbi, S.I.; Vanhaesebroeck, B. Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers. Proc. Natl. Acad. Sci. USA, 2007, 104(19), 7809-7814.
[http://dx.doi.org/10.1073/pnas.0700373104] [PMID: 17470792]
[29]
Huang, C.H.; Mandelker, D.; Schmidt-Kittler, O.; Samuels, Y.; Velculescu, V.E.; Kinzler, K.W.; Vogelstein, B.; Gabelli, S.B.; Amzel, L.M. The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science, 2007, 318(5857), 1744-1748.
[http://dx.doi.org/10.1126/science.1150799] [PMID: 18079394]
[30]
Walker, E.H.; Perisic, O.; Ried, C.; Stephens, L.; Williams, R.L. Structural insights into phosphoinositide 3-kinase catalysis and signalling. Nature, 1999, 402(6759), 313-320.
[http://dx.doi.org/10.1038/46319] [PMID: 10580505]
[31]
Downes, C.P.; Bennett, D.; McConnachie, G.; Leslie, N.R.; Pass, I.; MacPhee, C.; Patel, L.; Gray, A. Antagonism of PI 3-kinase-dependent signalling pathways by the tumour suppressor protein, PTEN. Biochem. Soc. Trans., 2001, 29(Pt 6), 846-851.
[http://dx.doi.org/10.1042/bst0290846] [PMID: 11709086]
[32]
Cantley, L.C.; Neel, B.G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl. Acad. Sci. USA, 1999, 96(8), 4240-4245.
[http://dx.doi.org/10.1073/pnas.96.8.4240] [PMID: 10200246]
[33]
Ortega-Molina, A.; Serrano, M. PTEN in cancer, metabolism, and aging. Trends Endocrinol. Metab., 2013, 24(4), 184-189.
[http://dx.doi.org/10.1016/j.tem.2012.11.002] [PMID: 23245767]
[34]
Song, M.S.; Salmena, L.; Pandolfi, P.P. The functions and regulation of the PTEN tumour suppressor. Nat. Rev. Mol. Cell Biol., 2012, 13(5), 283-296.
[http://dx.doi.org/10.1038/nrm3330] [PMID: 22473468]
[35]
Nagata, Y.; Lan, K.H.; Zhou, X.; Tan, M.; Esteva, F.J.; Sahin, A.A.; Klos, K.S.; Li, P.; Monia, B.P.; Nguyen, N.T.; Hortobagyi, G.N.; Hung, M.C.; Yu, D. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell, 2004, 6(2), 117-127.
[http://dx.doi.org/10.1016/j.ccr.2004.06.022] [PMID: 15324695]
[36]
Sun, L.; Liu, J.; Yuan, Q.; Xing, C.; Yuan, Y. Association between PTEN Gene IVS4 polymorphism and risk of cancer: a meta-analysis. PLoS One, 2014, 9(6) e98851
[http://dx.doi.org/10.1371/journal.pone.0098851] [PMID: 24901890]
[37]
Risso, G.; Blaustein, M.; Pozzi, B.; Mammi, P.; Srebrow, A. Akt/PKB: one kinase, many modifications. Biochem. J., 2015, 468(2), 203-214.
[http://dx.doi.org/10.1042/BJ20150041] [PMID: 25997832]
[38]
Bellacosa, A.; Kumar, C.C.; Di Cristofano, A.; Testa, J.R. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv. Cancer Res., 2005, 94, 29-86.
[http://dx.doi.org/10.1016/S0065-230X(05)94002-5] [PMID: 16095999]
[39]
Mundi, P.S.; Sachdev, J.; McCourt, C.; Kalinsky, K. AKT in cancer: new molecular insights and advances in drug development. Br. J. Clin. Pharmacol., 2016, 82(4), 943-956.
[http://dx.doi.org/10.1111/bcp.13021] [PMID: 27232857]
[40]
Xie, Y.; Naizabekov, S.; Chen, Z.; Tokay, T. Power of PTEN/AKT: Molecular switch between tumor suppressors and oncogenes. Oncol. Lett., 2016, 12(1), 375-378.
[http://dx.doi.org/10.3892/ol.2016.4636] [PMID: 27347153]
[41]
Hers, I.; Vincent, E.E.; Tavaré, J.M. Akt signalling in health and disease. Cell. Signal., 2011, 23(10), 1515-1527.
[http://dx.doi.org/10.1016/j.cellsig.2011.05.004] [PMID: 21620960]
[42]
Martelli, A.M.; Tabellini, G.; Bressanin, D.; Ognibene, A.; Goto, K.; Cocco, L.; Evangelisti, C. The emerging multiple roles of nuclear Akt. Biochim. Biophys. Acta, 2012, 1823(12), 2168-2178.
[http://dx.doi.org/10.1016/j.bbamcr.2012.08.017] [PMID: 22960641]
[43]
Osaki, M.; Oshimura, M.; Ito, H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis, 2004, 9(6), 667-676.
[http://dx.doi.org/10.1023/B:APPT.0000045801.15585.dd] [PMID: 15505410]
[44]
Samuels, Y.; Ericson, K. Oncogenic PI3K and its role in cancer. Curr. Opin. Oncol., 2006, 18(1), 77-82.
[http://dx.doi.org/10.1097/01.cco.0000198021.99347.b9] [PMID: 16357568]
[45]
Kaur, A.; Sharma, S. Mammalian target of rapamycin (mTOR) as a potential therapeutic target in various diseases. Inflammopharma., 2017, 25(3), 293-312.
[http://dx.doi.org/10.1007/s10787-017-0336-1] [PMID: 28417246]
[46]
Laplante, M.; Sabatini, D.M. mTOR signaling in growth control and disease. Cell, 2012, 149(2), 274-293.
[http://dx.doi.org/10.1016/j.cell.2012.03.017] [PMID: 22500797]
[47]
Chang, L.; Chiang, S.H.; Saltiel, A.R. Insulin signaling and the regulation of glucose transport. Mol. Med., 2004, 10(7-12), 65-71.
[http://dx.doi.org/10.2119/2005-00029.Saltiel] [PMID: 16307172]
[48]
Fu, Z.; Gilbert, E.R.; Liu, D. Regulation of insulin synthesis and secretion and pancreatic Beta-cell dysfunction in diabetes. Curr. Diabetes Rev., 2013, 9(1), 25-53.
[http://dx.doi.org/10.2174/157339913804143225] [PMID: 22974359]
[49]
Menon, S.; Dibble, C.C.; Talbott, G.; Hoxhaj, G.; Valvezan, A.J.; Takahashi, H.; Cantley, L.C.; Manning, B.D. Spatial control of the TSC complex integrates insulin and nutrient regulation of mTORC1 at the lysosome. Cell, 2014, 156(4), 771-785.
[http://dx.doi.org/10.1016/j.cell.2013.11.049] [PMID: 24529379]
[50]
Newton, A.C. Protein kinase C: structure, function, and regulation. J. Biol. Chem., 1995, 270(48), 28495-28498.
[http://dx.doi.org/10.1074/jbc.270.48.28495] [PMID: 7499357]
[51]
Faivre, S.; Kroemer, G.; Raymond, E. Current development of mTOR inhibitors as anticancer agents. Nat. Rev. Drug Discov., 2006, 5(8), 671-688.
[http://dx.doi.org/10.1038/nrd2062] [PMID: 16883305]
[52]
Wysocki, P.J. mTOR in renal cell cancer: modulator of tumor biology and therapeutic target. Expert Rev. Mol. Diagn., 2009, 9(3), 231-241.
[http://dx.doi.org/10.1586/erm.09.8] [PMID: 19379082]
[53]
Shaw, R.J.; Cantley, L.C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature, 2006, 441(7092), 424-430.
[http://dx.doi.org/10.1038/nature04869] [PMID: 16724053]
[54]
Hay, N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell, 2005, 8(3), 179-183.
[http://dx.doi.org/10.1016/j.ccr.2005.08.008] [PMID: 16169463]
[55]
Pawson, T. Introduction: protein kinases. FASEB J., 1994, 8(14), 1112-1113.
[http://dx.doi.org/10.1096/fasebj.8.14.7958615] [PMID: 7958615]
[56]
Sancak, Y.; Thoreen, C.C.; Peterson, T.R.; Lindquist, R.A.; Kang, S.A.; Spooner, E.; Carr, S.A.; Sabatini, D.M. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol. Cell, 2007, 25(6), 903-915.
[http://dx.doi.org/10.1016/j.molcel.2007.03.003] [PMID: 17386266]
[57]
Figlin, R.A.; Brown, E.; Armstrong, A.J.; Akerley, W.; Benson, A.B., III; Burstein, H.J.; Ettinger, D.S.; Febbo, P.G.; Fury, M.G.; Hudes, G.R.; Kies, M.S.; Kwak, E.L.; Morgan, R.J., Jr; Mortimer, J.; Reckamp, K.; Venook, A.P.; Worden, F.; Yen, Y. NCCN Task Force Report: mTOR inhibition in solid tumors. J. Natl. Compr. Canc. Netw., 2008, 6(5)(Suppl. 5), S1-S20.
[PMID: 18926092]
[58]
Sarbassov, D.D.; Guertin, D.A.; Ali, S.M.; Sabatini, D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science, 2005, 307(5712), 1098-1101.
[http://dx.doi.org/10.1126/science.1106148] [PMID: 15718470]
[59]
Miccò, M.; Sala, E.; Lakhman, Y.; Hricak, H.; Vargas, H.A. Imaging features of uncommon gynecologic cancers. AJR Am. J. Roentgenol., 2015, 205(6), 1346-1359.
[http://dx.doi.org/10.2214/AJR.14.12695] [PMID: 26587944]
[60]
Jemal, A.; Siegel, R.; Ward, E.; Murray, T.; Xu, J.; Thun, M. J. Cancer statistics, 2007. CA Cancer J. Clin., 2007, 57(1), 43-66.
[http://dx.doi.org/10.3322/canjclin.57.1.43] [PMID: 17237035]
[61]
Bader, A.A.; Winter, R.; Haas, J.; Tamussino, K.F. Where to look for the sentinel lymph node in cervical cancer. Am. J. Obstet. Gynecol., 2007, 197(6), 678.e1-678.e7.
[http://dx.doi.org/10.1016/j.ajog.2007.09.053] [PMID: 18060980]
[62]
Eifel, P.J.; Winter, K.; Morris, M.; Levenback, C.; Grigsby, P.W.; Cooper, J.; Rotman, M.; Gershenson, D.; Mutch, D.G. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J. Clin. Oncol., 2004, 22(5), 872-880.
[http://dx.doi.org/10.1200/JCO.2004.07.197] [PMID: 14990643]
[63]
Rob, L.; Strnad, P.; Robova, H.; Charvat, M.; Pluta, M.; Schlegerova, D.; Hrehorcak, M. Study of lymphatic mapping and sentinel node identification in early stage cervical cancer. Gynecol. Oncol., 2005, 98(2), 281-288.
[http://dx.doi.org/10.1016/j.ygyno.2005.04.016] [PMID: 15961145]
[64]
Vizcaino, A.P.; Moreno, V.; Bosch, F.X.; Muñoz, N.; Barros-Dios, X.M.; Borras, J.; Parkin, D.M. International trends in incidence of cervical cancer: II. Squamous-cell carcinoma. Int. J. Cancer, 2000, 86(3), 429-435.
[http://dx.doi.org/10.1002/(SICI)1097-0215(20000501)86:3<429:AID-IJC20>3.0.CO;2-D] [PMID: 10760834]
[65]
Barranger, E.; Delpech, Y.; Coutant, C.; Dubernard, G.; Uzan, S.; Darai, E. Laparoscopic sentinel node mapping using combined detection for endometrial cancer: a study of 33 cases--is it a promising technique? Am. J. Surg., 2009, 197(1), 1-7.
[http://dx.doi.org/10.1016/j.amjsurg.2007.10.021] [PMID: 18558387]
[66]
Di Donato, V.; Bellati, F.; Fischetti, M.; Plotti, F.; Perniola, G.; Panici, P.B. Vaginal cancer. Crit. Rev. Oncol. Hematol., 2012, 81(3), 286-295.
[http://dx.doi.org/10.1016/j.critrevonc.2011.04.004] [PMID: 21571543]
[67]
Crane, L.M.; Themelis, G.; Arts, H.J.; Buddingh, K.T.; Brouwers, A.H.; Ntziachristos, V.; van Dam, G.M.; van der Zee, A.G. Intraoperative near-infrared fluorescence imaging for sentinel lymph node detection in vulvar cancer: first clinical results. Gynecol. Oncol., 2011, 120(2), 291-295.
[http://dx.doi.org/10.1016/j.ygyno.2010.10.009] [PMID: 21056907]
[68]
Canavan, T.P.; Cohen, D. Vulvar cancer. Am. Fam. Physician, 2002, 66(7), 1269-1274.
[PMID: 12387439]
[69]
Burger, M.P.; Hollema, H.; Emanuels, A.G.; Krans, M.; Pras, E.; Bouma, J. The importance of the groin node status for the survival of T1 and T2 vulval carcinoma patients. Gynecol. Oncol., 1995, 57(3), 327-334.
[http://dx.doi.org/10.1006/gyno.1995.1151] [PMID: 7774836]
[70]
Levenback, C.; Burke, T.W.; Gershenson, D.M.; Morris, M.; Malpica, A.; Ross, M.I. Intraoperative lymphatic mapping for vulvar cancer. Obstet. Gynecol., 1994, 84(2), 163-167.
[PMID: 8041523]
[71]
Levenback, C.; Burke, T.W.; Morris, M.; Malpica, A.; Lucas, K.R.; Gershenson, D.M. Potential applications of intraoperative lymphatic mapping in vulvar cancer. Gynecol. Oncol., 1995, 59(2), 216-220.
[http://dx.doi.org/10.1006/gyno.1995.0011] [PMID: 7590476]
[72]
Beard, C.M.; Hartmann, L.C.; Atkinson, E.J.; O’Brien, P.C.; Malkasian, G.D.; Keeney, G.L.; Melton, L.J., III The epidemiology of ovarian cancer: a population-based study in Olmsted County, Minnesota, 1935-1991. Ann. Epidemiol., 2000, 10(1), 14-23.
[http://dx.doi.org/10.1016/S1047-2797(99)00045-9] [PMID: 10658685]
[73]
Hanna, L.; Adams, M. Prevention of ovarian cancer. Best Pract. Res. Clin. Obstet. Gynaecol., 2006, 20(2), 339-362.
[http://dx.doi.org/10.1016/j.bpobgyn.2005.10.016] [PMID: 16368271]
[74]
Colombo, N.; Van Gorp, T.; Parma, G.; Amant, F.; Gatta, G.; Sessa, C.; Vergote, I. Ovarian cancer. Crit. Rev. Oncol. Hematol., 2006, 60(2), 159-179.
[http://dx.doi.org/10.1016/j.critrevonc.2006.03.004] [PMID: 17018256]
[75]
Poveda, A. Management of recurrent ovarian cancer with systemic therapy. EJC Supplements, 2007, 1, 29-36.
[http://dx.doi.org/10.1016/S1359-6349(07)70013-7]
[76]
Rossouw, J.E.; Anderson, G.L.; Prentice, R.L. Writing group for the women’s health ınitiative ınvestigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women’s health ınitiative randomized controlled trial. JAMA, 2002, 288, 21-333.
[77]
Yang, H.P.; Anderson, W.F.; Rosenberg, P.S.; Trabert, B.; Gierach, G.L.; Wentzensen, N.; Cronin, K.A.; Sherman, M.E. Ovarian cancer incidence trends in relation to changing patterns of menopausal hormone therapy use in the United States. J. Clin. Oncol., 2013, 31(17), 2146-2151.
[http://dx.doi.org/10.1200/JCO.2012.45.5758] [PMID: 23650423]
[78]
Özcan, S.; Kurdak, H.; Bozdemir, N. Servikal kanser taraması. Turkish Journal of Family Practice, 2009, 2, 48-51.
[79]
Cain, J.M.; Ngan, H.; Garland, S.; Wright, T. FIGO Working Group on Combating Cervical Cancer. Control of cervical cancer: women’s options and rights. Int. J. Gynaecol. Obstet., 2009, 106(2), 141-143.
[http://dx.doi.org/10.1016/j.ijgo.2009.03.027] [PMID: 19535071]
[80]
Arbyn, M.; Raifu, A.O.; Weiderpass, E.; Bray, F.; Anttila, A. Trends of cervical cancer mortality in the member states of the European Union. Eur. J. Cancer, 2009, 45(15), 2640-2648.
[http://dx.doi.org/10.1016/j.ejca.2009.07.018] [PMID: 19695864]
[81]
Dunleavey, R. Cervical cancer: A guide for nurses; John Wiley & Sons: London, 2009.
[82]
Bats, A.S.; Buénerd, A.; Querleu, D.; Leblanc, E.; Daraï, E.; Morice, P.; Marret, H.; Gillaizeau, F.; Mathevet, P.; Lécuru, F. SENTICOL collaborative group. Diagnostic value of intraoperative examination of sentinel lymph node in early cervical cancer: a prospective, multicenter study. Gynecol. Oncol., 2011, 123(2), 230-235.
[http://dx.doi.org/10.1016/j.ygyno.2011.08.010] [PMID: 21893335]
[83]
Polat, A.; Aydın, Ö.; Düşmez, D. Mersin ilinde 1989- 1999 yılları arasında görülen kadın genital sistem tümörlerinin dağılımının değerlendirilmesi. Turkish J. Path., 2000, 16, 34-38.
[84]
Siegel, R.; Naishadham, D.; Jemal, A. Cancer statistics, 2013. CA Cancer J. Clin., 2013, 63(1), 11-30.
[http://dx.doi.org/10.3322/caac.21166] [PMID: 23335087]
[85]
Villa, L.L.; Costa, R.L.R.; Petta, C.A.; Andrade, R.P.; Paavonen, J.; Iversen, O.E.; Olsson, S.E.; Høye, J.; Steinwall, M.; Riis-Johannessen, G.; Andersson-Ellstrom, A.; Elfgren, K.; Krogh, Gv.; Lehtinen, M.; Malm, C.; Tamms, G.M.; Giacoletti, K.; Lupinacci, L.; Railkar, R.; Taddeo, F.J.; Bryan, J.; Esser, M.T.; Sings, H.L.; Saah, A.J.; Barr, E. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br. J. Cancer, 2006, 95(11), 1459-1466.
[http://dx.doi.org/10.1038/sj.bjc.6603469] [PMID: 17117182]
[86]
Keys, H.M.; Roberts, J.A.; Brunetto, V.L.; Zaino, R.J.; Spirtos, N.M.; Bloss, J.D.; Pearlman, A.; Maiman, M.A.; Bell, J.G. Gynecologic Oncology Group. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol., 2004, 92(3), 744-751.
[http://dx.doi.org/10.1016/j.ygyno.2003.11.048] [PMID: 14984936]
[87]
Amant, F.; Moerman, P.; Neven, P.; Timmerman, D.; Van Limbergen, E.; Vergote, I. Endometrial cancer. Lancet, 2005, 366(9484), 491-505.
[http://dx.doi.org/10.1016/S0140-6736(05)67063-8] [PMID: 16084259]
[88]
Purdie, D.M.; Green, A.C. Epidemiology of endometrial cancer. Best Pract. Res. Clin. Obstet. Gynaecol., 2001, 15(3), 341-354.
[http://dx.doi.org/10.1053/beog.2000.0180] [PMID: 11476557]
[89]
Stroup, A.M.; Harlan, L.C.; Trimble, E.L. Demographic, clinical, and treatment trends among women diagnosed with vulvar cancer in the United States. Gynecol. Oncol., 2008, 108(3), 577-583.
[http://dx.doi.org/10.1016/j.ygyno.2007.11.011] [PMID: 18155274]
[90]
Olaitan, A.; Murdoch, J. Clinical management of vulval cancer. Rev. Gyn. Prac., 2002, 2, 6-22.
[91]
Meads, C.; Sutton, A.J.; Rosenthal, A.N.; Małysiak, S.; Kowalska, M.; Zapalska, A.; Rogozińska, E.; Baldwin, P.; Ganesan, R.; Borowiack, E.; Barton, P.; Roberts, T.; Khan, K.; Sundar, S. Sentinel lymph node biopsy in vulval cancer: Systematic review and meta-analysis. Br. J. Cancer, 2014, 110(12), 2837-2846.
[http://dx.doi.org/10.1038/bjc.2014.205] [PMID: 24867697]
[92]
Moore, D.H. Chemotherapy and radiation therapy in the treatment of squamous cell carcinoma of the vulva: Are two therapies better than one? Gynecol. Oncol., 2009, 113(3), 379-383.
[http://dx.doi.org/10.1016/j.ygyno.2009.01.004] [PMID: 19232700]
[93]
International Cancer Research Partnership. Gynecologic cancers portfolio analysis., Available from: https://www.icrpartnership.org/library/file/3/ICRP_GYN_analysis.pdf (Accessed Nov 12, 2019)
[94]
Abu-Rustum, N.R. Sentinel lymph node mapping for endometrial cancer: a modern approach to surgical staging. J. Natl. Compr. Canc. Netw., 2014, 12(2), 288-297.
[http://dx.doi.org/10.6004/jnccn.2014.0026] [PMID: 24586087]
[95]
Robova, H.; Charvat, M.; Strnad, P.; Hrehorcak, M.; Taborska, K.; Skapa, P.; Rob, L. Lymphatic mapping in endometrial cancer: comparison of hysteroscopic and subserosal injection and the distribution of sentinel lymph nodes. Int. J. Gynecol. Cancer, 2009, 19(3), 391-394.
[http://dx.doi.org/10.1111/IGC.0b013e3181a1c0b1] [PMID: 19407565]
[96]
Miller, D.S. Patients with endometrial cancer at risk for lymphatic metastasis should undergo pelvic and periaortic lymphadenectomy as part of their initial surgery. Cancer, 2017, 123(2), 192-196.
[http://dx.doi.org/10.1002/cncr.30418] [PMID: 28067950]
[97]
Tuncer, Z.S. What is cervical cancer? Symptoms and treatment methods; Günalp, S; Tuncer, S., Ed.; Pelikan Publishing: Ankara, 2004, pp. 669-682.
[98]
Tuncer, S.; Salman, M.Ç. Gynecology and Obstetrics; Günalp, S; Tuncer, S., Ed.; Pelikan Publishing: Ankara, 2004, pp. 653-668.
[99]
Zemheri, E.; Koyuncuer, A. The importance of Pap test in early diagnosis of cervical cancers. STED, 2005, 14(1), 1-4.
[100]
Barut, A. Early diagnosis and treatment in cervical cancer. STED, 2000, 9, 97.
[101]
Brinton, L.A.; Lacey, J.V.; Sherman, M.E. Epidemiology of gynecologic cancers. In: Principles and Practice of Gynecologic Oncology; Hoskins, W.J., Ed.; Lippincott Williams & Wilkins: Philadelphia, 2005, pp. 3-9.
[102]
Atasü, T.; Şahmay, S. Gynecology; Nobel: Istanbul, 2001.
[103]
Koç, F.; Akşit, S.; Kurugöl, Z.; Koturoğlu, G.; Halıcıoğlu, O.; Aslan, A. Cervical cancer; Are women physicians well aware? Turkiye Klinikleri J. Gynecol. Obst., 2010, 20(5), 281-286.
[104]
Özgül, N. Cases of cervical cancer and cervical cancer in Turkey screening studies; Onur Publishing: Ankara, 2007.
[105]
Tingulstad, S.; Skjeldestad, F.E.; Halvorsen, T.B.; Hagen, B. Survival and prognostic factors in patients with ovarian cancer. Obstet. Gynecol., 2003, 101(5 Pt 1), 885-891.
[PMID: 12738145]
[106]
Cibula, D.; Abu-Rustum, N.R.; Dusek, L.; Zikán, M.; Zaal, A.; Sevcik, L.; Kenter, G.G.; Querleu, D.; Jach, R.; Bats, A.S.; Dyduch, G.; Graf, P.; Klat, J.; Lacheta, J.; Meijer, C.J.; Mery, E.; Verheijen, R.; Zweemer, R.P. Prognostic significance of low volume sentinel lymph node disease in early-stage cervical cancer. Gynecol. Oncol., 2012, 124(3), 496-501.
[http://dx.doi.org/10.1016/j.ygyno.2011.11.037] [PMID: 22120175]
[107]
Coggon, D.; Harris, E.C.; Brown, T.; Rice, T.; Palmer, K.T. Occupational mortality in England and Wales; Office of Public Sector Information: London, 2009.
[108]
Cronin, K.A.; Lake, A.J.; Scott, S.; Sherman, R.L.; Noone, A.M.; Howlader, N.; Henley, S.J.; Anderson, R.N.; Firth, A.U.; Ma, J.; Kohler, B.A.; Jemal, A. Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics. Cancer, 2018, 124(13), 2785-2800.
[http://dx.doi.org/10.1002/cncr.31551] [PMID: 29786848]
[109]
Sayasneh, A.; Ekechi, C.; Ferrara, L.; Kaijser, J.; Stalder, C.; Sur, S.; Timmerman, D.; Bourne, T. The characteristic ultrasound features of specific types of ovarian pathology (review). Int. J. Oncol. (review), 2015, 46(2), 445-458.
[http://dx.doi.org/10.3892/ijo.2014.2764] [PMID: 25406094]
[110]
Gynecologic cancers. What are the symptoms? Available on: www.cdc.gov/cancer/gynecologic/basic_info/symptoms.html (Accessed Nov 12, 2019)
[111]
Mathéron, H.M.; van den Berg, N.S.; Brouwer, O.R.; Kleinjan, G.H.; van Driel, W.J.; Trum, J.W.; Vegt, E.; Kenter, G.; van Leeuwen, F.W.; Valdés Olmos, R.A. Multimodal surgical guidance towards the sentinel node in vulvar cancer. Gynecol. Oncol., 2013, 131(3), 720-725.
[http://dx.doi.org/10.1016/j.ygyno.2013.09.007] [PMID: 24051219]
[112]
Hutteman, M.; van der Vorst, J.R.; Gaarenstroom, K.N.; Peters, A.A.; Mieog, J.S.; Schaafsma, B.E.; Lowik, C.W.; Frangioni, J.V.; van de Velde, C.J.; Vahrmeijer, A.L. Optimization of near-infrared fluorescent sentinel lymph node mapping for vulvar cancer. Am. J. Obstet. Gynecol, 2012, 206(1)89,1-5.
[http://dx.doi.org/10.1016/j.ajog.2011.07.039]
[113]
Lécuru, F.; Mathevet, P.; Querleu, D.; Leblanc, E.; Morice, P.; Daraï, E.; Marret, H.; Magaud, L.; Gillaizeau, F.; Chatellier, G.; Dargent, D. Bilateral negative sentinel nodes accurately predict absence of lymph node metastasis in early cervical cancer: results of the SENTICOL study. J. Clin. Oncol., 2011, 29(13), 1686-1691.
[http://dx.doi.org/10.1200/JCO.2010.32.0432] [PMID: 21444878]
[114]
Hauspy, J.; Beiner, M.; Harley, I.; Ehrlich, L.; Rasty, G.; Covens, A. Sentinel lymph nodes in early stage cervical cancer. Gynecol. Oncol., 2007, 105(2), 285-290.
[http://dx.doi.org/10.1016/j.ygyno.2007.02.008] [PMID: 17368525]
[115]
Cibula, D.; Kuzel, D.; Sláma, J.; Fischerova, D.; Dundr, P.; Freitag, P.; Zikán, M.; Pavlista, D.; Tomancova, V. Sentinel node (SLN) biopsy in the management of locally advanced cervical cancer. Gynecol. Oncol., 2009, 115(1), 46-50.
[http://dx.doi.org/10.1016/j.ygyno.2009.06.017] [PMID: 19646741]
[116]
ACOG Committee on Practice Bulletins. ACOG practice bulletin: Clinical management guidelines for obstetrician-gynecologists. Obstet. Gynecol., 2009, 109, 1-12.
[117]
Bodurtha Smith, A.J.; Fader, A.N.; Tanner, E.J. Sentinel lymph node assessment in endometrial cancer: a systematic review and meta-analysis. Am. J. Obstet. Gynecol., 2017, 216(5), 459-476.e10.
[http://dx.doi.org/10.1016/j.ajog.2016.11.1033] [PMID: 27871836]
[118]
Marnitz, S.; Köhler, C.; Müller, M.; Behrens, K.; Hasenbein, K.; Schneider, A. Indications for primary and secondary exenterations in patients with cervical cancer. Gynecol. Oncol., 2006, 103(3), 1023-1030.
[http://dx.doi.org/10.1016/j.ygyno.2006.06.027] [PMID: 16890276]
[119]
Ballester, M.; Dubernard, G.; Rouzier, R.; Barranger, E.; Darai, E. Use of the sentinel node procedure to stage endometrial cancer. Ann. Surg. Oncol., 2008, 15(5), 1523-1529.
[http://dx.doi.org/10.1245/s10434-008-9841-1] [PMID: 18322758]
[120]
Jelovac, D.; Armstrong, D.K. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J. Clin., 2011, 61(3), 183-203.
[http://dx.doi.org/10.3322/caac.20113] [PMID: 21521830]
[121]
Brown, J.; Smith, J.A.; Ramondetta, L.M.; Sood, A.K.; Ramirez, P.T.; Coleman, R.L.; Levenback, C.F.; Munsell, M.F.; Jung, M.; Wolf, J.K. Combination of gemcitabine and cisplatin is highly active in women with endometrial carcinoma: results of a prospective phase 2 trial. Cancer, 2010, 116(21), 4973-4979.
[http://dx.doi.org/10.1002/cncr.25498] [PMID: 20665499]
[122]
Garcia, A.A.; Hirte, H.; Fleming, G.; Yang, D.; Tsao-Wei, D.D.; Roman, L.; Groshen, S.; Swenson, S.; Markland, F.; Gandara, D.; Scudder, S.; Morgan, R.; Chen, H.; Lenz, H.J.; Oza, A.M. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J. Clin. Oncol., 2008, 26(1), 76-82.
[http://dx.doi.org/10.1200/JCO.2007.12.1939] [PMID: 18165643]
[123]
Sorbe, B.; Andersson, H.; Boman, K.; Rosenberg, P.; Kalling, M. Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel-long-term follow-up. Int. J. Gynecol. Cancer, 2008, 18(4), 803-808.
[http://dx.doi.org/10.1111/j.1525-1438.2007.01094.x] [PMID: 17944917]
[124]
Marth, C.; Landoni, F.; Mahner, S.; McCormack, M.; Gonzalez-Martin, A.; Colombo, N. ESMO Guidelines Committee. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol., 2017, 28((4 Suppl- 4)), iv72-iv83.
[http://dx.doi.org/10.1093/annonc/mdx220] [PMID: 28881916]
[125]
Armstrong, D.K.; Bundy, B.; Wenzel, L.; Huang, H.Q.; Baergen, R.; Lele, S.; Copeland, L.J.; Walker, J.L.; Burger, R.A. Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med., 2006, 354(1), 34-43.
[http://dx.doi.org/10.1056/NEJMoa052985] [PMID: 16394300]
[126]
Katsumata, N.; Yasuda, M.; Takahashi, F.; Isonishi, S.; Jobo, T.; Aoki, D.; Tsuda, H.; Sugiyama, T.; Kodama, S.; Kimura, E.; Ochiai, K.; Noda, K. Japanese Gynecologic Oncology Group. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet, 2009, 374(9698), 1331-1338.
[http://dx.doi.org/10.1016/S0140-6736(09)61157-0] [PMID: 19767092]
[127]
Obel, J.C.; Friberg, G.; Fleming, G.F. Chemotherapy in endometrial cancer. Clin. Adv. Hematol. Oncol., 2006, 4(6), 459-468.
[PMID: 16981669]
[128]
Heyman, J. Improvement of results in the treatment of uterine cancer. J. Am. Med. Assoc., 1947, 135(7), 412-416.
[http://dx.doi.org/10.1001/jama.1947.02890070014004] [PMID: 20264945]
[129]
Farnsworth, N.R.; Soejarto, D.D. Potential consequence of plant extinction in United States on the current and future availability of prescription drugs. Econ. Bot., 1985, 39, 231-240.
[http://dx.doi.org/10.1007/BF02858792]
[130]
Kinghorn, A.D.; Pan, L.; Fletcher, J.N.; Chai, H. The relevance of higher plants in lead compound discovery programs. J. Nat. Prod., 2011, 74(6), 1539-1555.
[http://dx.doi.org/10.1021/np200391c] [PMID: 21650152]
[131]
Tulp, M.; Bohlin, L. Rediscovery of known natural compounds: nuisance or goldmine? Bioorg. Med. Chem., 2005, 13(17), 5274-5282.
[http://dx.doi.org/10.1016/j.bmc.2005.05.067] [PMID: 16019216]
[132]
Cragg, G.M.; Newman, D.J.; Snader, K.M. Natural products in drug discovery and development. J. Nat. Prod., 1997, 60(1), 52-60.
[http://dx.doi.org/10.1021/np9604893] [PMID: 9014353]
[133]
Cragg, G.M.; Grothaus, P.G.; Newman, D.J. Impact of natural products on developing new anti-cancer agents. Chem. Rev., 2009, 109(7), 3012-3043.
[http://dx.doi.org/10.1021/cr900019j] [PMID: 19422222]
[134]
Newman, D.J.; Cragg, G.M. Natural products as sources of new drugs over the last 25 years. J. Nat. Prod., 2007, 70(3), 461-477.
[http://dx.doi.org/10.1021/np068054v] [PMID: 17309302]
[135]
Newman, D.J.; Cragg, G.M. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J. Nat. Prod., 2012, 75(3), 311-335.
[http://dx.doi.org/10.1021/np200906s] [PMID: 22316239]
[136]
Etienne-Grimaldi, M.C.; Boyer, J.C.; Thomas, F.; Quaranta, S.; Picard, N.; Loriot, M.A.; Narjoz, C.; Poncet, D.; Gagnieu, M.C.; Ged, C.; Broly, F.; Le Morvan, V.; Bouquié, R.; Gaub, M.P.; Philibert, L.; Ghiringhelli, F.; Le Guellec, C. Collective work by Groupe de Pharmacologie Clinique Oncologique (GPCO-Unicancer); French Réseau National de Pharmacogénétique Hospitalière (RNPGx). UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice. Fundam. Clin. Pharmacol., 2015, 29(3), 219-237.
[http://dx.doi.org/10.1111/fcp.12117] [PMID: 25817555]
[137]
Monk, B.J.; Sill, M.W.; McMeekin, D.S.; Cohn, D.E.; Ramondetta, L.M.; Boardman, C.H.; Benda, J.; Cella, D. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol., 2009, 27(28), 4649-4655.
[http://dx.doi.org/10.1200/JCO.2009.21.8909] [PMID: 19720909]
[138]
Thomas, C.J.; Rahier, N.J.; Hecht, S.M. Camptothecin: current perspectives. Bioorg. Med. Chem., 2004, 12(7), 1585-1604.
[http://dx.doi.org/10.1016/j.bmc.2003.11.036] [PMID: 15028252]
[139]
Gottlieb, J.A.; Luce, J.K. Treatment of malignant melanoma with camptothecin (NSC-100880). Cancer Chemother. Rep., 1972, 56(1), 103-105.
[PMID: 5030802]
[140]
Muggia, F.M.; Creaven, P.J.; Hansen, H.H.; Cohen, M.H.; Selawry, O.S. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother. Rep., 1972, 56(4), 515-521.
[PMID: 5081595]
[141]
Moertel, C.G.; Schutt, A.J.; Reitemeier, R.J.; Hahn, R.G. Phase II study of 5-azacytidine (NSC-102816) in the treatment of advanced gastrointestinal cancer. Cancer Chemother. Rep., 1972, 56(5), 649-652.
[PMID: 4119908]
[142]
Wall, M.E.; Wani, M.C.; Cook, C.E.; Palmer, K.H.; McPhail, A.T.; Sim, G.A. Plant antitumor agents. I. Isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J. Am. Chem. Soc., 1966, 88(16), 3888-3890.
[http://dx.doi.org/10.1021/ja00968a057]
[143]
Oberlies, N.H.; Kroll, D.J. Camptothecin and taxol: historic achievements in natural products research. J. Nat. Prod., 2004, 67(2), 129-135.
[http://dx.doi.org/10.1021/np030498t] [PMID: 14987046]
[144]
Wani, M.C.; Taylor, H.L.; Wall, M.E.; Coggon, P.; McPhail, A.T. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc., 1971, 93(9), 2325-2327.
[http://dx.doi.org/10.1021/ja00738a045] [PMID: 5553076]
[145]
Abaid, L.N.; Goldstein, B.H.; Micha, J.P.; Rettenmaier, M.A.; Brown, J.V., III; Markman, M. Improved overall survival with 12 cycles of single-agent paclitaxel maintenance therapy following a complete response to induction chemotherapy in advanced ovarian carcinoma. Oncology, 2010, 78(5-6), 389-393.
[http://dx.doi.org/10.1159/000320579] [PMID: 20798562]
[146]
Löwe, J.; Li, H.; Downing, K.H.; Nogales, E. Refined structure of alpha beta-tubulin at 3.5 A resolution. J. Mol. Biol., 2001, 313(5), 1045-1057.
[http://dx.doi.org/10.1006/jmbi.2001.5077] [PMID: 11700061]
[147]
Rowinsky, E.K. Paclitaxel pharmacology and other tumor types., Semin. Oncol, 1997, 24(19), S19-1-S19-12.
[148]
Mekhail, T.M.; Markman, M. Paclitaxel in cancer therapy. Expert Opin. Pharmacother., 2002, 3(6), 755-766.
[http://dx.doi.org/10.1517/14656566.3.6.755] [PMID: 12036415]
[149]
Chen, F.P.; Li, B.S.; Tang, C.H. Nanocomplexation between curcumin and soy protein isolate: influence on curcumin stability/bioaccessibility and in vitro protein digestibility. J. Agric. Food Chem., 2015, 63(13), 3559-3569.
[http://dx.doi.org/10.1021/acs.jafc.5b00448] [PMID: 25779681]
[150]
Galic, V.L.; Wright, J.D.; Lewin, S.N.; Herzog, T.J. Paclitaxel poliglumex for ovarian cancer. Expert Opin. Investig. Drugs, 2011, 20(6), 813-821.
[http://dx.doi.org/10.1517/13543784.2011.576666] [PMID: 21470062]
[151]
Stordal, B.; Pavlakis, N.; Davey, R. A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship. Cancer Treat. Rev., 2007, 33(8), 688-703.
[http://dx.doi.org/10.1016/j.ctrv.2007.07.013] [PMID: 17881133]
[152]
Gordaliza, M.; Castro, M.A.; Miguel del Corral, J.M.; López-Vázquez, M.L.; A. García, P. García-Grávalos, M.D.; San Feliciano, A. Synthesis and antineoplastic activity of cyclolignan aldehydes. Eur. J. Med. Chem., 2000, 35(7-8), 691-698.
[http://dx.doi.org/10.1016/S0223-5234(00)00176-8] [PMID: 10960184]
[153]
Hwang, J.H.; Yoo, H.J.; Lim, M.C.; Seo, S.S.; Park, S.Y.; Kang, S. Phase I clinical trial of alternating belotecan and oral etoposide in patients with platinum-resistant or heavily treated ovarian cancer. Anticancer Drugs, 2012, 23(3), 321-325.
[http://dx.doi.org/10.1097/CAD.0b013e32834ea5d0] [PMID: 22156765]
[154]
Vergote, I.; Leamon, C.P. Vintafolide: a novel targeted therapy for the treatment of folate receptor expressing tumors. Ther. Adv. Med. Oncol., 2015, 7(4), 206-218.
[http://dx.doi.org/10.1177/1758834015584763] [PMID: 26136852]
[155]
Choueiri, T.K.; Wesolowski, R.; Mekhail, T.M. Phenoxodiol: isoflavone analog with antineoplastic activity. Curr. Oncol. Rep., 2006, 8(2), 104-107.
[http://dx.doi.org/10.1007/s11912-006-0044-2] [PMID: 16507219]
[156]
Kelly, M.G.; Mor, G.; Husband, A.; O’Malley, D.M.; Baker, L.; Azodi, M.; Schwartz, P.E.; Rutherford, T.J. Phase II evaluation of phenoxodiol in combination with cisplatin or paclitaxel in women with platinum/taxane-refractory/resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers. Int. J. Gynecol. Cancer, 2011, 21(4), 633-639.
[http://dx.doi.org/10.1097/IGC.0b013e3182126f05] [PMID: 21412168]
[157]
Ohsumi, K.; Hatanaka, T.; Fujita, K.; Nakagawa, R.; Fukuda, Y.; Nihei, Y.; Suga, Y.; Morinaga, Y.; Akiyama, Y.; Tsuji, T. Syntheses and antitumor activity of cis-restricted combretastatins: 5-membered heterocyclic analogues. Bioorg. Med. Chem. Lett., 1998, 8(22), 3153-3158.
[http://dx.doi.org/10.1016/S0960-894X(98)00579-4] [PMID: 9873694]
[158]
Pettit, G.R.; Singh, S.B.; Boyd, M.R.; Hamel, E.; Pettit, R.K.; Schmidt, J.M.; Hogan, F. Antineoplastic agents. 291. Isolation and synthesis of combretastatins A-4, A-5, and A-6(1a). J. Med. Chem., 1995, 38(10), 1666-1672.
[http://dx.doi.org/10.1021/jm00010a011] [PMID: 7752190]
[159]
Rustin, G.J.; van der Burg, M.E.; Griffin, C.L.; Guthrie, D.; Lamont, A.; Jayson, G.C.; Kristensen, G.; Mediola, C.; Coens, C.; Qian, W.; Parmar, M.K.; Swart, A.M. MRC OV05; EORTC 55955 investigators. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet, 2010, 376(9747), 1155-1163.
[http://dx.doi.org/10.1016/S0140-6736(10)61268-8] [PMID: 20888993]
[160]
Zweifel, M.; Jayson, G.C.; Reed, N.S.; Osborne, R.; Hassan, B.; Ledermann, J.; Shreeves, G.; Poupard, L.; Lu, S.P.; Balkissoon, J.; Chaplin, D.J.; Rustin, G.J. Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. Ann. Oncol., 2011, 22(9), 2036-2041.
[http://dx.doi.org/10.1093/annonc/mdq708] [PMID: 21273348]
[161]
Azzoli, C.G.; Miller, V.A.; Ng, K.K.; Krug, L.M.; Spriggs, D.R.; Tong, W.P.; Riedel, E.R.; Kris, M.G. A phase I trial of perillyl alcohol in patients with advanced solid tumors. Cancer Chemother. Pharmacol., 2003, 51(6), 493-498.
[http://dx.doi.org/10.1007/s00280-003-0599-7] [PMID: 12695855]
[162]
Bailey, H.H.; Levy, D.; Harris, L.S.; Schink, J.C.; Foss, F.; Beatty, P.; Wadler, S. A phase II trial of daily perillyl alcohol in patients with advanced ovarian cancer: Eastern Cooperative Oncology Group Study E2E96. Gynecol. Oncol., 2002, 85(3), 464-468.
[http://dx.doi.org/10.1006/gyno.2002.6647] [PMID: 12051875]
[163]
Davis, J.M.; Murphy, E.A.; Carmichael, M.D.; Davis, B. Quercetin increases brain and muscle mitochondrial biogenesis and exercise tolerance. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2009, 296(4), R1071-R1077.
[http://dx.doi.org/10.1152/ajpregu.90925.2008] [PMID: 19211721]
[164]
Scambia, G.; Ranelletti, F.O.; Panici, P.B.; Piantelli, M.; Bonanno, G.; Vincenzo, R.; Ferrandina, G.; Rumi, C.; Larocca, L.M.; Mancuso, S. Inhibitory effect of quercetin on OVA 433 cells and presence oftype II oestrogen binding sites in primary ovarian tumors and cultured cells. Br. J. Cancer, 1990, 62(1), 942-946.
[http://dx.doi.org/10.1038/bjc.1990.414] [PMID: 2167724]
[165]
Gao, X.; Wang, B.; Wei, X.; Men, K.; Zheng, F.; Zhou, Y.; Zheng, Y.; Gou, M.; Huang, M.; Guo, G.; Huang, N.; Qian, Z.; Wei, Y. Anticancer effect and mechanism of polymer micelle-encapsulated quercetin on ovarian cancer. Nanoscale, 2012, 4(22), 7021-7030.
[http://dx.doi.org/10.1039/c2nr32181e] [PMID: 23044718]
[166]
Maciejczyk, A.; Surowiak, P. Quercetin inhibits proliferation and increases sensitivity of ovarian cancer cells to cisplatin and paclitaxel. Ginekol. Pol., 2013, 84(7), 590-595.
[http://dx.doi.org/10.17772/gp/1609] [PMID: 24032269]
[167]
Ye, F.; Xui, L.; Yi, J.; Zhang, W.; Zhang, D.Y. Anticancer activity of Scutellaria baicalensis and its potential mechanism. J. Altern. Complement. Med., 2002, 8(5), 567-572.
[http://dx.doi.org/10.1089/107555302320825075] [PMID: 12470437]
[168]
Yan, X.; Hu, Z.; Feng, Y.; Hu, X.; Yuan, J.; Zhao, S.D.; Zhang, Y.; Yang, L.; Shan, W.; He, Q.; Fan, L.; Kandalaft, L.E.; Tanyi, J.L.; Li, C.; Yuan, C.X.; Zhang, D.; Yuan, H.; Hua, K.; Lu, Y.; Katsaros, D.; Huang, Q.; Montone, K.; Fan, Y.; Coukos, G.; Boyd, J.; Sood, A.K.; Rebbeck, T.; Mills, G.B.; Dang, C.V.; Zhang, L. Comprehensive genomic characterization of long non-coding rnas across human cancers. Cancer Cell, 2015, 28(4), 529-540.
[http://dx.doi.org/10.1016/j.ccell.2015.09.006] [PMID: 26461095]
[169]
El-Dakhakhany, M. Studies on the chemical constitution of Egyptian N. sativa L. seeds. Planta Med., 1963, 11, 465-470.
[http://dx.doi.org/10.1055/s-0028-1100266]
[170]
Gali-Muhtasib, H.; Roessner, A.; Schneider-Stock, R. Thymoquinone: a promising anti-cancer drug from natural sources. Int. J. Biochem. Cell Biol., 2006, 38(8), 1249-1253.
[http://dx.doi.org/10.1016/j.biocel.2005.10.009] [PMID: 16314136]
[171]
Woo, C.C.; Kumar, A.P.; Sethi, G.; Tan, K.H. Thymoquinone: potential cure for inflammatory disorders and cancer. Biochem. Pharmacol., 2012, 83(4), 443-451.
[http://dx.doi.org/10.1016/j.bcp.2011.09.029] [PMID: 22005518]
[172]
Wilson, A.J.; Saskowski, J.; Barham, W.; Yull, F.; Khabele, D. Thymoquinone enhances cisplatin-response through direct tumor effects in a syngeneic mouse model of ovarian cancer. J. Ovarian Res., 2015, 8, 46.
[http://dx.doi.org/10.1186/s13048-015-0177-8] [PMID: 26215403]
[173]
Nessa, M.U.; Beale, P.; Chan, C.; Yu, J.Q.; Huq, F. Synergism from combinations of cisplatin and oxaliplatin with quercetin and thymoquinone in human ovarian tumour models. Anticancer Res., 2011, 31(11), 3789-3797.
[PMID: 22110201]
[174]
Cichewicz, R.H.; Kouzi, S.A. Chemistry, biological activity, and chemotherapeutic potential of betulinic acid for the prevention and treatment of cancer and HIV infection. Med. Res. Rev., 2004, 24(1), 90-114.
[http://dx.doi.org/10.1002/med.10053] [PMID: 14595673]
[175]
Fulda, S. Betulinic Acid for cancer treatment and prevention. Int. J. Mol. Sci., 2008, 9(6), 1096-1107.
[http://dx.doi.org/10.3390/ijms9061096] [PMID: 19325847]
[176]
Wang, Y.J.; Liu, J.B.; Dou, Y.C. Sequential treatment with betulinic acid followed by 5-fluorouracil shows synergistic cytotoxic activity in ovarian cancer cells. Int. J. Clin. Exp. Pathol., 2015, 8(1), 252-259.
[PMID: 25755712]
[177]
Chen, Y.J. Potential role of tetrandrine in cancer therapy. Acta Pharmacol. Sin., 2002, 23(12), 1102-1106.
[PMID: 12466047]
[178]
Choi, S.U.; Park, S.H.; Kim, K.H.; Choi, E.J.; Kim, S.; Park, W.K.; Zhang, Y.H.; Kim, H.S.; Jung, N.P.; Lee, C.O. The bisbenzylisoquinoline alkaloids, tetrandine and fangchinoline, enhance the cytotoxicity of multidrug resistance-related drugs via modulation of P-glycoprotein. Anticancer Drugs, 1998, 9(3), 255-261.
[http://dx.doi.org/10.1097/00001813-199803000-00008] [PMID: 9625436]
[179]
Zhang, Y.; Wang, C.; Wang, H.; Wang, K.; Du, Y.; Zhang, J. Combination of Tetrandrine with cisplatin enhances cytotoxicity through growth suppression and apoptosis in ovarian cancer in vitro and in vivo. Cancer Lett., 2011, 304(1), 21-32.
[http://dx.doi.org/10.1016/j.canlet.2011.01.022] [PMID: 21333438]
[180]
Sun, Y.F.; Wink, M. Tetrandrine and fangchinoline, bisbenzylisoquinoline alkaloids from Stephania tetrandra can reverse multidrug resistance by inhibiting P-glycoprotein activity in multidrug resistant human cancer cells. Phytomedicine, 2014, 21(8-9), 1110-1119.
[http://dx.doi.org/10.1016/j.phymed.2014.04.029] [PMID: 24856768]
[181]
Kashyap, D.; Garg, V.K.; Tuli, H.S.; Yerer, M.B.; Sak, K.; Sharma, A.K.; Kumar, M.; Aggarwal, V.; Sandhu, S.S. Fisetin and quercetin: Promising flavonoids with chemopreventive potential. Biomolecules, 2019, 9(5), 174.
[http://dx.doi.org/10.3390/biom9050174] [PMID: 31064104]
[182]
Gábor, M.; Eperjessy, E. Antibacterial effect of fisetin and fisetinidin. Nature, 1966, 212(5067), 1273.
[http://dx.doi.org/10.1038/2121273a0] [PMID: 21090477]
[183]
Chou, R.H.; Hsieh, S.C.; Yu, Y.L.; Huang, M.H.; Huang, Y.C.; Hsieh, Y.H. Fisetin inhibits migration and invasion of human cervical cancer cells by down-regulating urokinase plasminogen activator expression through suppressing the p38 MAPK-dependent NF-κB signaling pathway. PLoS One, 2013, 8(8) e71983
[http://dx.doi.org/10.1371/journal.pone.0071983] [PMID: 23940799]
[184]
Uche, F.; Li, W.W.; Richardson, A.; Greenhough, T.J. Anti-ovarian cancer activities of alkaloids from Triclisia subcordata olive (Menispermecaea). Planta Med., 2014, 80, 7.
[http://dx.doi.org/10.1055/s-0034-1382585]
[185]
Şahin, F.; Avcu, F.; Saydam, G. Red grape seed extract and its main components resveratrol and borax show cytotoxic effect on malignant cell lines. Turk. J. Haematol., 2004, 21(3), 53-54.
[186]
Benitez, D.A.; Pozo-Guisado, E.; Alvarez-Barrientos, A.; Fernandez-Salguero, P.M.; Castellón, E.A. Mechanisms involved in resveratrol-induced apoptosis and cell cycle arrest in prostate cancer-derived cell lines. J. Androl., 2007, 28(2), 282-293.
[http://dx.doi.org/10.2164/jandrol.106.000968] [PMID: 17050787]
[187]
Riles, W.L.; Erickson, J.; Nayyar, S.; Atten, M.J.; Attar, B.M.; Holian, O. Resveratrol engages selective apoptotic signals in gastric adenocarcinoma cells. World J. Gastroenterol., 2006, 12(35), 5628-5634.
[http://dx.doi.org/10.3748/wjg.v12.i35.5628] [PMID: 17007014]
[188]
Ayla, Ş.; Öktem, G.; Bilir, A. MDAH-2774 Investigation of different drug effects with nitric oxide synthase changes in human ovarian cancer three-dimensional cell culture. Cerrahpasa Med J., 2009, 40, 88-96.
[189]
Barcelo, S.; Gardiner, J.M.; Gescher, A.; Chipman, J.K. CYP2E1-mediated mechanism of anti-genotoxicity of the broccoli constituent sulforaphane. Carcinogenesis, 1996, 17(2), 277-282.
[http://dx.doi.org/10.1093/carcin/17.2.277] [PMID: 8625450]
[190]
Chaudhuri, D.; Orsulic, S.; Ashok, B.T. Antiproliferative activity of sulforaphane in Akt-overexpressing ovarian cancer cells. Mol. Cancer Ther., 2007, 6(1), 334-345.
[http://dx.doi.org/10.1158/1535-7163.MCT-06-0404] [PMID: 17237292]
[191]
Fimognari, C.; Hrelia, P. Sulforaphane as a promising molecule for fighting cancer. Mutat. Res., 2007, 635(2-3), 90-104.
[http://dx.doi.org/10.1016/j.mrrev.2006.10.004] [PMID: 17134937]
[192]
Kim, M.K.; Kim, K.; Han, J.Y.; Lim, J.M.; Song, Y.S. Modulation of inflammatory signaling pathways by phytochemicals in ovarian cancer. Genes Nutr., 2011, 6(2), 109-115.
[http://dx.doi.org/10.1007/s12263-011-0209-y] [PMID: 21484164]
[193]
Cappelletti, V.; Fioravanti, L.; Miodini, P.; Di Fronzo, G. Genistein blocks breast cancer cells in the G(2)M phase of the cell cycle. J. Cell. Biochem., 2000, 79(4), 594-600.
[http://dx.doi.org/10.1002/1097-4644(20001215)79:4<594:AID-JCB80>3.0.CO;2-4] [PMID: 10996850]
[194]
López-Lazaro, M.; Willmore, E.; Austin, C.A. Cells lacking DNA topoisomerase II beta are resistant to genistein. J. Nat. Prod., 2007, 70(5), 763-767.
[http://dx.doi.org/10.1021/np060609z] [PMID: 17411092]
[195]
Rhode, J.; Fogoros, S.; Zick, S.; Wahl, H.; Griffith, K.A.; Huang, J.; Liu, J.R. Ginger inhibits cell growth and modulates angiogenic factors in ovarian cancer cells. BMC Complement. Altern. Med., 2007, 7, 44.
[http://dx.doi.org/10.1186/1472-6882-7-44] [PMID: 18096028]
[196]
Bava, S.V.; Sreekanth, C.N.; Thulasidasan, A.K.; Anto, N.P.; Cheriyan, V.T.; Puliyappadamba, V.T.; Menon, S.G.; Ravichandran, S.D.; Anto, R.J. Akt is upstream and MAPKs are downstream of NF-κB in paclitaxel-induced survival signaling events, which are down-regulated by curcumin contributing to their synergism. Int. J. Biochem. Cell Biol., 2011, 43(3), 331-341.
[http://dx.doi.org/10.1016/j.biocel.2010.09.011] [PMID: 20883815]
[197]
Sreekanth, C.N.; Bava, S.V.; Sreekumar, E.; Anto, R.J. Molecular evidences for the chemosensitizing efficacy of liposomal curcumin in paclitaxel chemotherapy in mouse models of cervical cancer. Oncogene, 2011, 30(28), 3139-3152.
[http://dx.doi.org/10.1038/onc.2011.23] [PMID: 21317920]
[198]
Ganta, S.; Amiji, M. Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol. Pharm., 2009, 6(3), 928-939.
[http://dx.doi.org/10.1021/mp800240j] [PMID: 19278222]
[199]
Beevers, C.S.; Chen, L.; Liu, L.; Luo, Y.; Webster, N.J.; Huang, S. Curcumin disrupts the Mammalian target of rapamycin-raptor complex. Cancer Res., 2009, 69(3), 1000-1008.
[http://dx.doi.org/10.1158/0008-5472.CAN-08-2367] [PMID: 19176385]
[200]
Ravindran, J.; Prasad, S.; Aggarwal, B.B. Curcumin and cancer cells: how many ways can curry kill tumor cells selectively? AAPS J., 2009, 11(3), 495-510.
[http://dx.doi.org/10.1208/s12248-009-9128-x] [PMID: 19590964]
[201]
Choi, J.; Moon, S.; Bae, H.; Kim, Y.W.; Lee, D.; Kim, S.; Seo, Y.; Wang, H.S.; Choi, Y.W.; Lee, M.W.; Ko, J.H.; Lim, I.; Bang, H. Alnus sibirica extracts suppress the expression of inflammatory cytokines induced by lipopolysaccharides, tumor necrosis factor-alpha, and interferon-gamma in human dermal fibroblasts. Molecules, 2019, 24(16), 2883.
[http://dx.doi.org/10.3390/molecules24162883] [PMID: 31398908]
[202]
Farrand, L.; Kim, J.Y.; Byun, S.; Im-aram, A.; Lee, J.; Suh, J.Y.; Lee, K.W.; Lee, H.J.; Tsang, B.K. The diarylheptanoid hirsutenone sensitizes chemoresistant ovarian cancer cells to cisplatin via modulation of apoptosis-inducing factor and X-linked inhibitor of apoptosis. J. Biol. Chem., 2014, 289(3), 1723-1731.
[http://dx.doi.org/10.1074/jbc.M113.513879] [PMID: 24247248]
[203]
Keck, A.S.; Finley, J.W. Cruciferous vegetables: cancer protective mechanisms of glucosinolate hydrolysis products and selenium. Integr. Cancer Ther., 2004, 3(1), 5-12.
[http://dx.doi.org/10.1177/1534735403261831] [PMID: 15035868]
[204]
Kim, Y.S.; Milner, J.A. Targets for indole-3-carbinol in cancer prevention. J. Nutr. Biochem., 2005, 16(2), 65-73.
[http://dx.doi.org/10.1016/j.jnutbio.2004.10.007] [PMID: 15681163]
[205]
Acharya, A.; Das, I.; Singh, S.; Saha, T. Chemopreventive properties of indole-3-carbinol, diindolylmethane and other constituents of cardamom against carcinogenesis. Recent Pat. Food Nutr. Agric., 2010, 2(2), 166-177.
[http://dx.doi.org/10.2174/1876142911002020166] [PMID: 20653562]
[206]
Bradlow, H.L.; Zeligs, M.A. Diindolylmethane (DIM) spontaneously forms from indole-3-carbinol (I3C) during cell culture experiments. In Vivo, 2010, 24(4), 387-391.
[PMID: 20668304]
[207]
Saw, C.L.; Cintrón, M.; Wu, T.Y.; Guo, Y.; Huang, Y.; Jeong, W.S.; Kong, A.N. Pharmacodynamics of dietary phytochemical indoles I3C and DIM: Induction of Nrf2-mediated phase II drug metabolizing and antioxidant genes and synergism with isothiocyanates. Biopharm. Drug Dispos., 2011, 32(5), 289-300.
[http://dx.doi.org/10.1002/bdd.759] [PMID: 21656528]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 20
ISSUE: 20
Year: 2020
Page: [1772 - 1790]
Pages: 19
DOI: 10.2174/1568026620666200416084440
Price: $65

Article Metrics

PDF: 20
HTML: 1



Related Article(s)

Most Downloaded Article(s)